Shenzhen Kangtai Biological Products Co., Ltd.

Shenzhen Stock Exchange 300601.SZ

Shenzhen Kangtai Biological Products Co., Ltd. EBITDA for the year ending December 31, 2023: USD 182.41 M

Shenzhen Kangtai Biological Products Co., Ltd. EBITDA is USD 182.41 M for the year ending December 31, 2023, a 284,075.04% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Shenzhen Kangtai Biological Products Co., Ltd. EBITDA for the year ending December 31, 2022 was USD 64.19 K, a -99.98% change year over year.
Shenzhen Kangtai Biological Products Co., Ltd. EBITDA for the year ending December 31, 2021 was USD 298.78 M, a 121.23% change year over year.
Shenzhen Kangtai Biological Products Co., Ltd. EBITDA for the year ending December 31, 2020 was USD 135.05 M, a 24.28% change year over year.
Shenzhen Kangtai Biological Products Co., Ltd. EBITDA for the year ending December 31, 2019 was USD 108.67 M, a 30.61% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shenzhen Stock Exchange: 300601.SZ

Shenzhen Kangtai Biological Products Co., Ltd.

CEO	Ms. Hui Zhou
IPO Date	Feb. 8, 2017
Location	China
Headquarters	Science and Technology Park
Employees	1,902
Sector	Healthcare
Industries Vaccines

Description

Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined with live attenuated vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, and HIB conjugate vaccine. It has an agreement between YTB and Yong Tai Berhad in relation to the development and commercialization of Covid-19 inactivated vaccine in Malaysia. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.

Key trends

Past 5 years